24/7 Market News Snapshot 06 June, 2025 – Phio Pharmaceuticals Corp. Common Stock (NASDAQ:PHIO)

June 6, 2025

DENVER, Colo., 06 June, 2025 (www.247marketnews.com) – (NASDAQ:PHIO) are discussed in this article.
Phio Pharmaceuticals Corp. has experienced a notable uptick in market activity, with its stock price opening at $2.54 and surging by 23.74% to reach $3.044, reflecting heightened investor enthusiasm. The company recorded a trading volume of 1.07 million shares, showcasing significant interest amid its innovative developments in the biotech arena. This growing momentum positions Phio favorably as it explores advancements in its proprietary INTASYL® gene silencing technology, which is pivotal to its cancer therapeutics efforts.

To bolster its strategic initiatives, Phio Pharmaceuticals announced the appointment of Robert Infarinato as Vice President of Strategic Development, effective June 9, 2025. Infarinato, previously serving as Chief Financial Officer, will now concentrate on business development initiatives aimed at maximizing the applications of the INTASYL technology. The company is currently advancing a pipeline of approximately 30 compounds, with the INTASYL compound PH-762 undergoing a Phase 1b clinical trial. This trial has yielded promising interim results regarding safety and efficacy in treating skin cancers, such as cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.

Additionally, Lisa Carson has been appointed as Vice President of Finance and Administration. With over two decades of financial experience, including her role as VP, Finance and Controller at Prelude Therapeutics, her expertise is expected to strengthen Phio’s financial strategies during this pivotal expansion phase.

Robert Bitterman, CEO and President of Phio Pharmaceuticals, emphasized that these key appointments reflect the company’s dedication to harnessing the potential within its INTASYL portfolio. As Phio Pharmaceuticals continues to progress toward innovative treatment solutions in the cancer landscape, the firm remains committed to enhancing its clinical programs for patients worldwide.

Related news for (PHIO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.